TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2012 - 2025)
TherapeuticsMD's (TXMD) quarterly Asset Writedowns and Impairment came in at $1.3 million in Q1 2025, up 17914.29% quarter-over-quarter from $7000.0 in Q4 2024.
Powered by 
Analysis
TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2012 - 2025) Analysis & Trends
TherapeuticsMD (TXMD) has reported Asset Writedowns and Impairment for 14 consecutive years, with $1.3 million the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2025 stood at $1.3 million (changed N/A YoY), and the FY2024 full-year result was $1.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment climbed to $1.3 million in Q1 2025 per TXMD's latest filing, from $7000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.3 million in Q1 2025 and bottomed at -$7000.0 in Q4 2021.
- Historically, Asset Writedowns and Impairment has averaged $266888.9 across 5 years, with a median of $215000.0 in 2021.
- The widest YoY moves for Asset Writedowns and Impairment: up 462.08% in 2021, down 101.4% in 2021.
- Over 5 years, Asset Writedowns and Impairment stood at -$7000.0 in 2021, then jumped by 3928.57% to $268000.0 in 2022, then sank by 77.99% to $59000.0 in 2023, then slumped by 88.14% to $7000.0 in 2024, then soared by 17914.29% to $1.3 million in 2025.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.3 million, $7000.0, and $59000.0 for Q1 2025, Q4 2024, and Q1 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 7,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Jun 30, 2022 | 268,000.00 |
| Mar 31, 2022 | 274,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | 95,000.00 |
| Jun 30, 2021 | 215,000.00 |
| Mar 31, 2021 | 230,000.00 |
| Dec 31, 2020 | 500,000.00 |
| Sep 30, 2020 | 600,000.00 |
| Jun 30, 2020 | -59,379.00 |
| Mar 31, 2020 | -122,621.00 |
| Dec 31, 2019 | 222,903.00 |
| Sep 30, 2019 | -72,403.00 |
| Jun 30, 2019 | 85,216.00 |
| Mar 31, 2019 | 82,284.00 |
| Dec 31, 2018 | -15,453.00 |
| Sep 30, 2018 | 193,451.00 |
| Jun 30, 2018 | 15,069.00 |